Cargando…

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration. Liquid biopsy might allow real-time sampling of patients for PD-L1 through the course of the dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicolazzo, Chiara, Raimondi, Cristina, Mancini, MariaLaura, Caponnetto, Salvatore, Gradilone, Angela, Gandini, Orietta, Mastromartino, Maria, del Bene, Gabriella, Prete, Alessandra, Longo, Flavia, Cortesi, Enrico, Gazzaniga, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995431/ https://www.ncbi.nlm.nih.gov/pubmed/27553175 http://dx.doi.org/10.1038/srep31726

Ejemplares similares

Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal
por: Gradilone, Angela, et al.
Publicado: (2011)

Letter to the Editor: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Nicolazzo, Chiara, et al.
Publicado: (2017)

EpCAM(low) Circulating Tumor Cells: Gold in the Waste
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Molecular markers in circulating tumour cells from metastatic colorectal cancer patients
por: Gazzaniga, Paola, et al.
Publicado: (2010)

Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer
por: Magri, Valentina, et al.
Publicado: (2023)

Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo
por: Raimondi, Cristina, et al.
Publicado: (2014)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Significance of Circulating Tumor Cells in Soft Tissue Sarcoma
por: Nicolazzo, Chiara, et al.
Publicado: (2015)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma
por: Nicolazzo, Chiara, et al.
Publicado: (2018)

Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding
por: Shin, Jong, et al.
Publicado: (2021)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

Sequential Isolation and Characterization of Single CTCs and Large CTC Clusters in Metastatic Colorectal Cancer Patients
por: Francescangeli, Federica, et al.
Publicado: (2021)

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
por: Guo, Liting, et al.
Publicado: (2017)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
por: Yang, Yuanquan, et al.
Publicado: (2022)

Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
por: Liu, Wai Nam, et al.
Publicado: (2022)

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
por: Fessas, Petros, et al.
Publicado: (2017)

Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation
por: Liu, Wenping, et al.
Publicado: (2020)

Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study
por: Sciortino, Carolina, et al.
Publicado: (2022)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
por: Pedersen, Jesper Geert, et al.
Publicado: (2022)

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
por: Ieranò, Caterina, et al.
Publicado: (2022)

IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer
por: Ding, Guoping, et al.
Publicado: (2019)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

PD-1抑制剂Nivolumab治疗相关的皮肤毒性1例
Publicado: (2019)

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma
por: Griffin, Liezel L., et al.
Publicado: (2018)

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
por: Nakahara, Yoshiro, et al.
Publicado: (2018)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report
por: Paraghamian, Sarah E., et al.
Publicado: (2017)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Merkel Cell Carcinoma of the Retroperitoneum with No Identifiable Primary Site
por: Rossini, Daniele, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_l49p5q61h8t6l5349s4bmkk3s1